Morgan Stanley analyst Erin Wright raised the firm’s price target on Cencora (COR) to $288 from $263 and keeps an Equal Weight rating on the shares. While policy will be “front and center” with varying degrees of exposure, or lack there of, across the Healthcare Services and Technology space, the focus will also be on indications of underlying utilization trends across MCOs, distributors, providers, labs, animal and dental into Q1, the analyst tells investors in a preview for the group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cardinal Health price target raised to $155 from $150 at BofA
- Cencora price target raised to $285 from $270 at BofA
- McKesson price target raised to $755 from $665 at BofA
- Cencora price target raised to $274 from $251 at Wells Fargo
- Cencora’s Mixed Regional Performance and Valuation Concerns Justify Hold Rating